- Expansion of Oncolytics' lead breast cancer program into a new disease subtype
- Seek synergies between pelareorep and retifanlimab checkpoint inhibitor
SAN DIEGO, Calif. and CALGARY, Alberta, Aug. 26, 2020 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC) today announced the first patient has been dosed in the Company's investigator-sponsored phase 2 study of pelareorep-anti-PD-1 combination therapy in unresectable locally advanced or metastatic triple-negative breast cancer (TNBC). The study, known as IRENE, is co-sponsored by Oncolytics, the Rutgers Cancer Institute of New Jersey, and Incyte. Participants in the multi-center study receive pelareorep in combination with Incyte's anti-PD-1 checkpoint inhibitor retifanlimab (INCMGA00012).